ERBB2 and neoplasm: According to the 2009 ASCO/CAP guidelines, HER2 genetic heterogeneity is defined as the presence of ≥5% to <50% of infiltrating tumor cells with a ratio ≥2.2 when using dual probes or ≥6 HER2 signals/cell using single probes26.